Global Patient Derived Xenograft/PDX Models Market Size, Status and Forecast 2019-2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 93

Report ID: 1821

Patient derived xenografts (PDX) are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. PDX models are used to create an environment that allows for the natural growth of cancer, its monitoring, and corresponding treatment evaluations for the original patient.
Several types of immunodeficient mice can be used to establish PDX models: athymic nude mice, severely compromised immune deficient (SCID) mice, NOD-SCID mice, and recombination-activating gene 2 (Rag2)-knockout mice. The mice used must be immunocompromised to prevent transplant rejection. The NOD-SCID mouse is considered more immunodeficient than the nude mouse, and therefore is more commonly used for PDX models because the NOD-SCID mouse does not produce natural killer cells.
In 2018, the global Patient Derived Xenograft/PDX Models market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Patient Derived Xenograft/PDX Models status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Patient Derived Xenograft/PDX Models development in United States, Europe and China.

The key players covered in this study
Crown Bioscience
The Jackson Laboratory
Champions Oncology
Charles River Laboratories
WuXi Apptec
Oncodesign
Horizon Discovery
Pharmatest Services
Hera Biolabs
EPO Berlin-Buch
Xentech
Urolead

Market segment by Type, the product can be split into
Mice Models
Rat Models

Market segment by Application, split into
Pre-clinical Drug Development and Basic Cancer Research
Biomarker Analysis

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Patient Derived Xenograft/PDX Models status, future forecast, growth opportunity, key market and key players.
To present the Patient Derived Xenograft/PDX Models development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Patient Derived Xenograft/PDX Models are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Patient Derived Xenograft/PDX Models Market Size Growth Rate by Type (2014-2025)
1.4.2 Mice Models
1.4.3 Rat Models
1.5 Market by Application
1.5.1 Global Patient Derived Xenograft/PDX Models Market Share by Application (2014-2025)
1.5.2 Pre-clinical Drug Development and Basic Cancer Research
1.5.3 Biomarker Analysis
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Patient Derived Xenograft/PDX Models Market Size
2.2 Patient Derived Xenograft/PDX Models Growth Trends by Regions
2.2.1 Patient Derived Xenograft/PDX Models Market Size by Regions (2014-2025)
2.2.2 Patient Derived Xenograft/PDX Models Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Patient Derived Xenograft/PDX Models Market Size by Manufacturers
3.1.1 Global Patient Derived Xenograft/PDX Models Revenue by Manufacturers (2014-2019)
3.1.2 Global Patient Derived Xenograft/PDX Models Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Patient Derived Xenograft/PDX Models Market Concentration Ratio (CR5 and HHI)
3.2 Patient Derived Xenograft/PDX Models Key Players Head office and Area Served
3.3 Key Players Patient Derived Xenograft/PDX Models Product/Solution/Service
3.4 Date of Enter into Patient Derived Xenograft/PDX Models Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Patient Derived Xenograft/PDX Models Market Size by Type (2014-2019)
4.2 Global Patient Derived Xenograft/PDX Models Market Size by Application (2014-2019)

5 United States
5.1 United States Patient Derived Xenograft/PDX Models Market Size (2014-2019)
5.2 Patient Derived Xenograft/PDX Models Key Players in United States
5.3 United States Patient Derived Xenograft/PDX Models Market Size by Type
5.4 United States Patient Derived Xenograft/PDX Models Market Size by Application

6 Europe
6.1 Europe Patient Derived Xenograft/PDX Models Market Size (2014-2019)
6.2 Patient Derived Xenograft/PDX Models Key Players in Europe
6.3 Europe Patient Derived Xenograft/PDX Models Market Size by Type
6.4 Europe Patient Derived Xenograft/PDX Models Market Size by Application

7 China
7.1 China Patient Derived Xenograft/PDX Models Market Size (2014-2019)
7.2 Patient Derived Xenograft/PDX Models Key Players in China
7.3 China Patient Derived Xenograft/PDX Models Market Size by Type
7.4 China Patient Derived Xenograft/PDX Models Market Size by Application

8 Japan
8.1 Japan Patient Derived Xenograft/PDX Models Market Size (2014-2019)
8.2 Patient Derived Xenograft/PDX Models Key Players in Japan
8.3 Japan Patient Derived Xenograft/PDX Models Market Size by Type
8.4 Japan Patient Derived Xenograft/PDX Models Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Patient Derived Xenograft/PDX Models Market Size (2014-2019)
9.2 Patient Derived Xenograft/PDX Models Key Players in Southeast Asia
9.3 Southeast Asia Patient Derived Xenograft/PDX Models Market Size by Type
9.4 Southeast Asia Patient Derived Xenograft/PDX Models Market Size by Application

10 India
10.1 India Patient Derived Xenograft/PDX Models Market Size (2014-2019)
10.2 Patient Derived Xenograft/PDX Models Key Players in India
10.3 India Patient Derived Xenograft/PDX Models Market Size by Type
10.4 India Patient Derived Xenograft/PDX Models Market Size by Application

11 Central & South America
11.1 Central & South America Patient Derived Xenograft/PDX Models Market Size (2014-2019)
11.2 Patient Derived Xenograft/PDX Models Key Players in Central & South America
11.3 Central & South America Patient Derived Xenograft/PDX Models Market Size by Type
11.4 Central & South America Patient Derived Xenograft/PDX Models Market Size by Application

12 International Players Profiles
12.1 Crown Bioscience
12.1.1 Crown Bioscience Company Details
12.1.2 Company Description and Business Overview
12.1.3 Patient Derived Xenograft/PDX Models Introduction
12.1.4 Crown Bioscience Revenue in Patient Derived Xenograft/PDX Models Business (2014-2019)
12.1.5 Crown Bioscience Recent Development
12.2 The Jackson Laboratory
12.2.1 The Jackson Laboratory Company Details
12.2.2 Company Description and Business Overview
12.2.3 Patient Derived Xenograft/PDX Models Introduction
12.2.4 The Jackson Laboratory Revenue in Patient Derived Xenograft/PDX Models Business (2014-2019)
12.2.5 The Jackson Laboratory Recent Development
12.3 Champions Oncology
12.3.1 Champions Oncology Company Details
12.3.2 Company Description and Business Overview
12.3.3 Patient Derived Xenograft/PDX Models Introduction
12.3.4 Champions Oncology Revenue in Patient Derived Xenograft/PDX Models Business (2014-2019)
12.3.5 Champions Oncology Recent Development
12.4 Charles River Laboratories
12.4.1 Charles River Laboratories Company Details
12.4.2 Company Description and Business Overview
12.4.3 Patient Derived Xenograft/PDX Models Introduction
12.4.4 Charles River Laboratories Revenue in Patient Derived Xenograft/PDX Models Business (2014-2019)
12.4.5 Charles River Laboratories Recent Development
12.5 WuXi Apptec
12.5.1 WuXi Apptec Company Details
12.5.2 Company Description and Business Overview
12.5.3 Patient Derived Xenograft/PDX Models Introduction
12.5.4 WuXi Apptec Revenue in Patient Derived Xenograft/PDX Models Business (2014-2019)
12.5.5 WuXi Apptec Recent Development
12.6 Oncodesign
12.6.1 Oncodesign Company Details
12.6.2 Company Description and Business Overview
12.6.3 Patient Derived Xenograft/PDX Models Introduction
12.6.4 Oncodesign Revenue in Patient Derived Xenograft/PDX Models Business (2014-2019)
12.6.5 Oncodesign Recent Development
12.7 Horizon Discovery
12.7.1 Horizon Discovery Company Details
12.7.2 Company Description and Business Overview
12.7.3 Patient Derived Xenograft/PDX Models Introduction
12.7.4 Horizon Discovery Revenue in Patient Derived Xenograft/PDX Models Business (2014-2019)
12.7.5 Horizon Discovery Recent Development
12.8 Pharmatest Services
12.8.1 Pharmatest Services Company Details
12.8.2 Company Description and Business Overview
12.8.3 Patient Derived Xenograft/PDX Models Introduction
12.8.4 Pharmatest Services Revenue in Patient Derived Xenograft/PDX Models Business (2014-2019)
12.8.5 Pharmatest Services Recent Development
12.9 Hera Biolabs
12.9.1 Hera Biolabs Company Details
12.9.2 Company Description and Business Overview
12.9.3 Patient Derived Xenograft/PDX Models Introduction
12.9.4 Hera Biolabs Revenue in Patient Derived Xenograft/PDX Models Business (2014-2019)
12.9.5 Hera Biolabs Recent Development
12.10 EPO Berlin-Buch
12.10.1 EPO Berlin-Buch Company Details
12.10.2 Company Description and Business Overview
12.10.3 Patient Derived Xenograft/PDX Models Introduction
12.10.4 EPO Berlin-Buch Revenue in Patient Derived Xenograft/PDX Models Business (2014-2019)
12.10.5 EPO Berlin-Buch Recent Development
12.11 Xentech
12.12 Urolead

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details